Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

by · The Cerbat Gem

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 21,400 shares, a drop of 51.8% from the August 15th total of 44,400 shares. Based on an average daily trading volume, of 2,040,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.6% of the shares of the stock are short sold. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,040,000 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Lixte Biotechnology

An institutional investor recently raised its position in Lixte Biotechnology stock. FNY Investment Advisers LLC boosted its position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Free Report) by 172.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 107,000 shares of the company’s stock after purchasing an additional 67,781 shares during the period. FNY Investment Advisers LLC owned about 3.40% of Lixte Biotechnology worth $129,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Lixte Biotechnology to a “hold” rating in a research note on Saturday, August 9th.

Check Out Our Latest Stock Analysis on Lixte Biotechnology

Lixte Biotechnology Trading Up 14.0%

Shares of NASDAQ:LIXT opened at $6.01 on Friday. The company has a market capitalization of $27.41 million, a price-to-earnings ratio of -4.66 and a beta of 0.46. Lixte Biotechnology has a 12 month low of $0.64 and a 12 month high of $6.26. The firm’s 50-day moving average is $4.08 and its 200 day moving average is $2.23.

Lixte Biotechnology (NASDAQ:LIXT – Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.29) EPS for the quarter.

Lixte Biotechnology Company Profile

(Get Free Report)

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.

Featured Articles